Quince Therapeutics Inc. (QNCX) shares are under renewed pressure as the company navigates a challenging landscape marked by Nasdaq compliance issues, a going concern warning, and a failed clinical trial. The stock was last quoted at $1.15 before Monday's regular session open, according to a late-Friday filing.
Nantahala Capital Discloses Stake
Nantahala Capital Management amended a passive ownership filing, reporting beneficial ownership of 4.53 million shares, or 7.52% of the class. The filing, a Schedule 13G/A, indicated that Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 4,528,302 shares as of March 31. This includes shares that could be acquired within 60 days through convertible securities.
Going Concern and No Product Candidates
Quince's latest quarterly filing, the 10-Q for the period ended March 31, revealed that the company has no current product candidates and raised substantial doubt about its ability to continue as a going concern. The company reported $18.2 million in cash and cash equivalents as of March 31, and is preserving cash while weighing strategic alternatives. A going concern warning is an accounting term used when there is doubt a company can continue operating for at least another year without additional funding.
Reverse Stock Split and Nasdaq Compliance
Quince is seeking shareholder approval for another reverse stock split at its June 11 annual meeting. The proposed split range is 1-for-10 to 1-for-100. A reverse stock split reduces the number of shares outstanding while increasing the nominal price per share, but does not change a holder's percentage ownership. The company previously completed a 1-for-10 reverse stock split effective on Nasdaq on April 13 after falling below the exchange's minimum bid-price rule.
While Quince has regained compliance with Nasdaq's $1 minimum bid price requirement, it remains out of compliance with the $50 million minimum market value of listed securities rule. The initial deadline to regain compliance is September 14. Market value of listed securities is one of Nasdaq's tests to determine if a company is large enough to maintain its listing.
Failed Trial and Strategic Alternatives
Quince's stock decline earlier this year followed the failed Phase 3 NEAT trial of eDSP in ataxia-telangiectasia, a rare inherited neurodegenerative and immune disorder. The study did not achieve statistical significance on its primary and key secondary endpoints, and Quince subsequently stopped clinical development of eDSP. Chief Executive and Chief Medical Officer Dirk Thye noted in March that settling European Investment Bank debt was a meaningful step forward as the company restructures and evaluates alternatives. A $5.5 million payment resolved approximately $16.4 million of obligations.
Competitive Landscape and Risks
Adding to the challenges, privately held IntraBio reported in January that its Phase 3 trial of levacetylleucine in ataxia-telangiectasia met its primary and key secondary endpoints, with plans for regulatory submissions in the U.S. and Europe. Quince's own program failed shortly after, leaving the stock more exposed to balance-sheet and deal-related headlines than to pipeline progress. The broader biotech sector was also soft, with the SPDR S&P Biotech ETF and the iShares Nasdaq Biotechnology ETF trading lower in premarket activity.
Quince has stated that it has no signed strategic transaction, may not secure funding on favorable terms or at all, and could face material consequences if Nasdaq delists the stock, including reduced liquidity and a weaker position for any potential reverse merger.
